share_log

人福医药(600079.SH):枸橼酸舒芬太尼注射液获得临床试验批准通知书

Humanwell Healthcare (600079.SH): Clinical trial approval notice received for citric acid sufentanil injection.

Gelonghui Finance ·  Jul 25 06:12

On July 25th, Gelunhui announced that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as "Yichang Humanwell", with the company holding 80% of its equity), recently received the "Drug clinical trial approval notice" signed and issued by the National Medical Products Administration for Glycine fentanyl injection. Fentanyl is a potent opioid analgesic and a specific μ-opioid receptor agonist.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment